Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy

被引:159
作者
Thomson, MM [1 ]
Pérez-Alvarez, L [1 ]
Nájera, R [1 ]
机构
[1] Inst Salud Carlos III, Ctr Nacl Microbiol, Dept Viral Pathogenesis, Madrid 28220, Spain
关键词
D O I
10.1016/S1473-3099(02)00343-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Since their initial expansion in human beings roughly seven decades ago in central Africa, the HIV-1 pandemic strains have diversified extensively through mutation and recombination. 24 circulating genetic forms of the main HIV-1 group are presently recognised, including 11 subtypes or sub-subtypes and 13 circulating recombinant forms. New genetic forms are being introduced in different areas of the world, changing the molecular epidemiology of the infection. It is generally agreed that the control of the HIV-1 pandemic requires the development of vaccines that efficiently protect against the range of HIV-1 genetic forms. The introduction of effective antiretroviral therapies in areas of high HIV-1 prevalence may also contribute to the control of the pandemic, as has been documented in developed countries. Efficient targeting of the extensive genetic diversity of HIV-1 constitutes one of the major challenges in present efforts against the pandemic, although the significance of HIV-1 genetic forms for vaccine development and therapy remains to be defined.
引用
收藏
页码:461 / 471
页数:11
相关论文
共 81 条
[31]   High proportion of unrelated HIV-1 intersubtype recombinants in the Mbeya region of southwest Tanzania [J].
Hoelscher, M ;
Kim, B ;
Maboko, L ;
Mhalu, F ;
von Sonnenburg, F ;
Birx, DL ;
McCutchan, FE .
AIDS, 2001, 15 (12) :1461-1470
[32]  
Holm-Hansen C, 2000, AIDS RES HUM RETROV, V16, P867
[33]   Molecular epidemiology of viral infections - How sequence information helps us understand the evolution and dissemination of viruses [J].
Hungnes, O ;
Jonassen, TO ;
Jonassen, CM ;
Grinde, B .
APMIS, 2000, 108 (02) :81-97
[34]  
JOST S, 2002, 9 C RETR OPP INF WAS
[35]   Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda [J].
Kaleebu, P ;
French, N ;
Mahe, C ;
Yirrell, D ;
Watera, C ;
Lyagoba, F ;
Nakiyingi, J ;
Rutebemberwa, A ;
Morgan, D ;
Weber, J ;
Gilks, C ;
Whitworth, J .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (09) :1244-1250
[36]   Human immunodeficiency virus type 1 subtypes differ in disease progression [J].
Kanki, PJ ;
Hamel, DJ ;
Sankalé, JL ;
Hsieh, CC ;
Thior, I ;
Barin, F ;
Woodcock, SA ;
Guèye-Ndiaye, A ;
Zhang, E ;
Montano, M ;
Siby, T ;
Marlink, R ;
NDoye, I ;
Essex, ME .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :68-73
[37]   Evaluation of United States-licensed human immunodeficiency virus immunoassays for detection of group M viral variants [J].
Koch, WH ;
Sullivan, PS ;
Roberts, C ;
Francis, K ;
Downing, R ;
Mastro, TD ;
Nkengasong, J ;
Hu, D ;
Masciotra, S ;
Schable, C ;
Lal, RB .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (03) :1017-1020
[38]   Timing the ancestor of the HIV-1 pandemic strains [J].
Korber, B ;
Muldoon, M ;
Theiler, J ;
Gao, F ;
Gupta, R ;
Lapedes, A ;
Hahn, BH ;
Wolinsky, S ;
Bhattacharya, T .
SCIENCE, 2000, 288 (5472) :1789-1796
[39]   Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement [J].
Kostrikis, LG ;
Cao, YZ ;
Ngai, H ;
Moore, JP ;
Ho, DD .
JOURNAL OF VIROLOGY, 1996, 70 (01) :445-458
[40]   RETRACTED: Fusion-competent vaccines broad neutralization of primary isolates of HIV (Retracted article. See vol 296, pg 1025, 2002) [J].
LaCasse, RA ;
Follis, KE ;
Trahey, M ;
Scarborough, JD ;
Littman, DR ;
Nunberg, JH .
SCIENCE, 1999, 283 (5400) :357-362